Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 329

1.

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.

Br J Dermatol. 2008 Mar;158(3):549-57. Epub 2007 Nov 28.

PMID:
18047521
[PubMed - indexed for MEDLINE]
2.

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.

J Dermatolog Treat. 2007;18(1):25-31.

PMID:
17365264
[PubMed - indexed for MEDLINE]
3.

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

J Dermatolog Treat. 2007;18(6):341-50.

PMID:
18058494
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators.

Br J Dermatol. 2008 Mar;158(3):558-66. Epub 2007 Nov 28.

PMID:
18047523
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000.

PMID:
21110526
[PubMed - indexed for MEDLINE]
6.

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.

Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.

Health Qual Life Outcomes. 2008 Oct 2;6:75. doi: 10.1186/1477-7525-6-75.

PMID:
18831744
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.

Health Qual Life Outcomes. 2006 Sep 27;4:71.

PMID:
17005043
[PubMed - indexed for MEDLINE]
Free PMC Article
8.
9.
10.

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11.

PMID:
18187944
[PubMed - indexed for MEDLINE]
11.

Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.

Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.

J Rheumatol. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1.

PMID:
22045836
[PubMed - indexed for MEDLINE]
Free Article
12.

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.

Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.

Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20.

PMID:
21173304
[PubMed - indexed for MEDLINE]
13.

Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr.

J Drugs Dermatol. 2004 Jan-Feb;3(1):27-38.

PMID:
14964744
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.

Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.

PMID:
21910713
[PubMed - indexed for MEDLINE]
15.

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.

Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.

Br J Dermatol. 2012 Dec;167(6):1374-81. doi: 10.1111/bjd.12000. Epub 2012 Nov 2.

PMID:
22897348
[PubMed - indexed for MEDLINE]
16.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
[PubMed - indexed for MEDLINE]
17.

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.

Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA.

Health Qual Life Outcomes. 2013 May 10;11:82. doi: 10.1186/1477-7525-11-82.

PMID:
23663752
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Am J Gastroenterol. 2008 Dec;103(12):3132-41. doi: 10.1111/j.1572-0241.2008.02175.x. Epub 2008 Oct 3. Erratum in: Am J Gastroenterol. 2009 Jul;104(7):1894.

PMID:
18853973
[PubMed - indexed for MEDLINE]
19.

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.

Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1436-43. doi: 10.1111/j.1468-3083.2011.04308.x. Epub 2011 Oct 31.

PMID:
22035157
[PubMed - indexed for MEDLINE]
20.

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.

Spuls PI, Hooft L.

Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

PMID:
23013312
[PubMed]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk